But what about vaccines from Moderna and Novavax? Here's what we know. Australia's medicines watchdog has approved Pfizer's new COVID-19 vaccine and it's set to be available in the coming months.

Novavax, Inc. (NASDAQ:NVAX) Q3 2024 Earnings Call Transcript ... The trial will enroll adults aged 65 years and older and is ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

The findings were based on blood samples collected from 50 COVID-19 patients in Australia collected up to 18 months after ...

The market expects Novavax (NVAX) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus ...

In early pandemic days, Novavax (NASDAQ: NVAX) shares soared as investors bet on the company's ability to bring a coronavirus vaccine to market. But as the biotech fell behind in the race and ...

Nov 5 (Reuters) - Novavax (NVAX.O), opens new tab said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency (UKHSA) related to its COVID-19 ...

Novavax Inc.’s stock tumbled 19% early Wednesday after the company said the Food and Drug Administration has placed a clinical hold on its COVID-19-and-flu combination and stand-alone flu ...

Novavax (NVAX) closed the latest trading day at $10.07, indicating a -1.76% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.16% for the day.

Novavax reports Q3 2024 sales of $84.5 million, beating estimates, with a net loss of $121 million. EPS improves, FDA approves new vaccine, and revenue guidance is lowered. Vandana Singh FDA Gives ...

Novavax, Inc. ( NASDAQ: NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET ...